KRAS mutations are the most common mutations in non-small cell lung cancer (NSCLC)
with adenocarcinoma histology. KRAS mutations result in the activation of the RAF–MEK …

ABSTRACT KRAS mutations in non-small-cell lung cancer (NSCLC) are associated with
poor prognosis. Trametinib, a selective inhibitor of MEK1/MEK2, demonstrated similar …

The RAS–RAF–MEK–ERK pathway regulates processes involved in the proliferation and
survival of cells. KRAS mutations, prevalent in approximately 30% of patients with non-small …

Background Oncogenic KRAS mutations represent the largest genomically defined subset of
lung cancer, and are associated with activation of the RAS/RAF/MEK/ERK pathway. There …

8026 Background: KRAS mutations are present in 20% of NSCLC and are associated with
primary resistance to erlotinib (E). KRAS mutations result in constitutive activation of the …

Introduction Activation of the RAS/RAF/MEK/ERK pathway may confer resistance to
chemotherapy in non-small cell lung cancer (NSCLC). Selumetinib (AZD6244 …

Background KRAS mutations in NSCLC are associated with a lack of response to epidermal
growth factor receptor inhibitors. Selumetinib (AZD6244; ARRY-142886) is an oral selective …

8029 Background: KRAS mutations are detected in 25% of NSCLC, and there are no
approved targeted therapies for this subset of NSCLC. D, an approved second-line …

8027 Background: Lung cancer patients with mutated KRAS tumors present a treatment
challenge. Trametinib+ pemetrexed (pem) enhanced growth inhibition and apoptosis …

Importance Lung cancer is the leading cause of cancer deaths worldwide, with non–small-
cell lung cancer (NSCLC) constituting more than 80% of all lung cancers. Non–small-cell …